(Wall Street Journal) – Not long after the FDA wrapped its preliminary investigation of GLP-1 receptor agonists and suicidal thoughts or actions, the European Medicines Agency (EMA) followed suit with its own review. In April, the EMA said it also didn’t find a causal link.

This conclusion was largely based on two studies of patients on semaglutide (Ozempic, Rybelsus, Wegovy) that looked at patients with overweight or obesity and with type 2 diabetes. Both found a significantly lower risk of suicidal ideation among users compared with users of non-GLP-1 medications.

Despite both agencies’ reports early in the year, the topic sustained interest throughout 2024, with new analyses drawing conflicting conclusions. (Read More)